Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XOMA Corporation
Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?
The sponsor of an ophthalmic formulation of bevacizumab is set to speak up for its marketing authorization application during a European Medicines Agency oral explanation meeting.
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
- Large Molecule
- Other Names / Subsidiaries
- Enumeral Biomedical Inc.
- XOMA Ltd.